|
Take heed to this text  |
Supply: EndoQuest
EndoQuest Robotics Inc. and Omnivision have partnered to combine Omnivision’s CameraCubeChip into EndoQuest’s surgical robotic system.
Santa Clara, Calif.-based Omnivision develops semiconductor methods, together with superior digital imaging and contact show expertise.
Houston-based EndoQuest designed its system to deal with unmet wants in gastrointestinal and different endoluminal surgical procedures. The firm mentioned its proprietary expertise navigates inside the physique’s lumina areas such because the gut. This offers the precision and suppleness for minimally invasive interventions, which might enhance affected person outcomes, it mentioned.
EndoQuest added that its platform permits therapeutic endoscopists and surgeons to function by a trans-oral or trans-anal method. Final month, the corporate raised $42 million. Final week, the U.S. Meals and Drug Administration’s Safer Applied sciences Program (STeP) accepted the surgical robotic system.
Omnivision to allow clearer surgical visualization
Omnivision designed the CameraCubeChip visualization system with its PureCel Plus-S pixel expertise.
PureCel Plus-S permits “excessive full-well capability, zero blooming and decrease energy consumption with crisp, clear, life-like photographs,” mentioned Tehzeeb Gunja, director of medical advertising at Omnivision. He added that the compact, medical-grade providing may take affected person care and surgical visualization “to the subsequent stage.”
“We’re excited to have the ability to incorporate Omnivision’s market-leading sensor expertise into the visualization part of our first-of-its-kind platform,” mentioned Kurt Azarbarzin, CEO of EndoQuest Robotics, in a launch. “We acknowledge that superior imaging is important to enhancing doctor capabilities, particularly contained in the lumen of the gastrointestinal (GI) tract. Omnivision’s latest expertise is good for our versatile robotic system.”
EndoQuest expects STeP to speed up entry
STeP offers a streamlined growth and market evaluation course of for eligible medical units with the objective of accelerating affected person entry with out compromising security and efficacy. The FDA launched STeP in 2021, modeling this system on its breakthrough units designation program.
STeP covers units that might enhance the protection of remedies or diagnostics. They have to be designed to deal with underlying illnesses or circumstances thought-about much less severe than these handled or identified by units eligible for breakthrough designation.
“We consider that our distinctive robotic platform will improve doctor management, precision, and effectivity, enabling safer and more practical minimally invasive remedies,” said Azarbarzin. “We stay up for working with the FDA to deliver the Versatile Robotic System to market and supply physicians and sufferers a brand new, scar-free method for all kinds of medical circumstances and procedures.”
Editor’s observe: This text was syndicated from MassDevice, a sibling website to The Robotic Report.
